168 related articles for article (PubMed ID: 8787171)
1. The value of magnetic resonance imaging in diagnosis and monitoring of treatment in multiple sclerosis.
Bekiesińska-Figatowska M; Walecki J; Stelmasiak Z
Acta Neurobiol Exp (Wars); 1996; 56(1):171-6. PubMed ID: 8787171
[TBL] [Abstract][Full Text] [Related]
2. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study.
O'Connor P; Comi G; Montalban X; Antel J; Radue EW; de Vera A; Pohlmann H; Kappos L;
Neurology; 2009 Jan; 72(1):73-9. PubMed ID: 19122034
[TBL] [Abstract][Full Text] [Related]
3. Brain atrophy evolution and lesion load accrual in multiple sclerosis: a 2-year follow-up study.
Tedeschi G; Dinacci D; Comerci M; Lavorgna L; Savettieri G; Quattrone A; Livrea P; Patti F; Morra VB; Servillo G; Orefice G; Paciello M; Prinster A; Coniglio G; Bonavita S; Di Costanzo A; Bellacosa A; Valentino P; Quarantelli M; Brunetti A; Salemi G; D'Amelio M; Simone I; Salvatore M; Bonavita V; Alfano B
Mult Scler; 2009 Feb; 15(2):204-11. PubMed ID: 18987104
[TBL] [Abstract][Full Text] [Related]
4. [Acute posterior cord lesions in multiple sclerosis. An MRI study of the clinical course in 20 cases].
Pou Serradell A; Roquer González J; Perich Alsina X
Rev Neurol (Paris); 2000 Dec; 156(12):1126-35. PubMed ID: 11139729
[TBL] [Abstract][Full Text] [Related]
5. Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden.
Benedict RH; Weinstock-Guttman B; Fishman I; Sharma J; Tjoa CW; Bakshi R
Arch Neurol; 2004 Feb; 61(2):226-30. PubMed ID: 14967771
[TBL] [Abstract][Full Text] [Related]
6. Contribution of white matter lesions to gray matter atrophy in multiple sclerosis: evidence from voxel-based analysis of T1 lesions in the visual pathway.
Sepulcre J; Goñi J; Masdeu JC; Bejarano B; Vélez de Mendizábal N; Toledo JB; Villoslada P
Arch Neurol; 2009 Feb; 66(2):173-9. PubMed ID: 19204153
[TBL] [Abstract][Full Text] [Related]
7. Voxel-wise assessment of progression of regional brain atrophy in relapsing-remitting multiple sclerosis.
Battaglini M; Giorgio A; Stromillo ML; Bartolozzi ML; Guidi L; Federico A; De Stefano N
J Neurol Sci; 2009 Jul; 282(1-2):55-60. PubMed ID: 19286193
[TBL] [Abstract][Full Text] [Related]
8. MR in the diagnosis and monitoring of multiple sclerosis: an overview.
Rovira A; León A
Eur J Radiol; 2008 Sep; 67(3):409-14. PubMed ID: 18434066
[TBL] [Abstract][Full Text] [Related]
9. Optimizing brain MRI protocols in the follow-up of patients with multiple sclerosis T2-weighted MRI of the brain after the administration of gadopentetate dimeglumine.
Taschner CA; Kirsch EC; Scheffler K; Wetzel SG; Schulte-Mönting J; Kappos L; Radü EW
Magn Reson Imaging; 2005 Apr; 23(3):469-74. PubMed ID: 15862648
[TBL] [Abstract][Full Text] [Related]
10. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis.
Narayana PA; Doyle TJ; Lai D; Wolinsky JS
Ann Neurol; 1998 Jan; 43(1):56-71. PubMed ID: 9450769
[TBL] [Abstract][Full Text] [Related]
11. Diffusion-weighted MR of the brain: methodology and clinical application.
Mascalchi M; Filippi M; Floris R; Fonda C; Gasparotti R; Villari N
Radiol Med; 2005 Mar; 109(3):155-97. PubMed ID: 15775887
[TBL] [Abstract][Full Text] [Related]
12. [Brain damage assessment in patients with multiple sclerosis by means of MRI].
Titlić M; Orsolić K; Tonkić A; Jukić I; Lusić I
Acta Med Croatica; 2008 Feb; 62(1):5-8. PubMed ID: 18365493
[TBL] [Abstract][Full Text] [Related]
13. Magnetic resonance imaging of epilepsy in multiple sclerosis: a case control study. Implications for treatment trials with 4-aminopyridine.
Truyen L; Barkhof F; Frequin ST; Polman CH; Tobi H; Hommes OR; Valk J
Mult Scler; 1996 Feb; 1(4):213-7. PubMed ID: 9345437
[TBL] [Abstract][Full Text] [Related]
14. The contribution of diffusion-weighted MR imaging in multiple sclerosis during acute attack.
Yurtsever I; Hakyemez B; Taskapilioglu O; Erdogan C; Turan OF; Parlak M
Eur J Radiol; 2008 Mar; 65(3):421-6. PubMed ID: 17587524
[TBL] [Abstract][Full Text] [Related]
15. Characterization of tissue damage in multiple sclerosis by nuclear magnetic resonance.
Barkhof F; van Walderveen M
Philos Trans R Soc Lond B Biol Sci; 1999 Oct; 354(1390):1675-86. PubMed ID: 10603619
[TBL] [Abstract][Full Text] [Related]
16. Gray matter atrophy in multiple sclerosis: a longitudinal study.
Fisher E; Lee JC; Nakamura K; Rudick RA
Ann Neurol; 2008 Sep; 64(3):255-65. PubMed ID: 18661561
[TBL] [Abstract][Full Text] [Related]
17. [Necrotic plaque formation in a case of frontal lobe multiple sclerosis].
Sugano M; Hirayama K; Saito T; Tsukamoto T; Yamamoto T
Rinsho Shinkeigaku; 1992 Jun; 32(6):621-5. PubMed ID: 1424342
[TBL] [Abstract][Full Text] [Related]
18. [MRI diagnosis of multiple cerebral sclerosis].
Cheng GX; Wu HW; Zhang J; Liang LN; Zhang XL
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(8):1372-5. PubMed ID: 18753063
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis.
Romine JS; Sipe JC; Koziol JA; Zyroff J; Beutler E
Proc Assoc Am Physicians; 1999; 111(1):35-44. PubMed ID: 9893155
[TBL] [Abstract][Full Text] [Related]
20. Cladribine in treatment of chronic progressive multiple sclerosis.
Sipe JC; Romine JS; Koziol JA; McMillan R; Zyroff J; Beutler E
Lancet; 1994 Jul; 344(8914):9-13. PubMed ID: 7912347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
